Hi, what are you looking for?
A new approach replaces rilpivirine with lenacapavir, a long-acting drug that attacks HIV in a different way.
Injections were found to be more effective at keeping the virus suppressed than the tablets, so efforts should be made to make this treatment...
Long-acting HIV therapies are becoming an increasingly competitive treatment category. While efficacy remains essential, differentiation is now shifting towards factors such as dosing convenience,...
A one-time regimen of therapies given to newborns within three days of birth may permanently clear the virus.
Although modern medicines have transformed HIV into a manageable long-term condition, taking medication every day can still contribute to stigma and treatment fatigue for...
Although new HIV infections and AIDS-related deaths are at their lowest levels in more than 30 years, the current HIV response is extremely fragile.
An unexpectedly high percentage of children born with HIV and started treatment within 48 hours of life exhibit biomarkers by two years of age...